These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 29555635)

  • 1. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
    Tran N; Rybak MJ
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
    Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights.
    Kebriaei R; Rice SA; Singh NB; Stamper KC; Nguyen L; Sheikh Z; Rybak MJ
    J Antimicrob Chemother; 2020 Oct; 75(10):2894-2901. PubMed ID: 32591820
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Davis KP; McDermott LA; Snydman DR; Aldridge BB
    Microbiol Spectr; 2024 Aug; 12(8):e0097624. PubMed ID: 38916355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
    Vidaillac C; Leonard SN; Rybak MJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
    Leonard SN; Supple ME; Gandhi RG; Patel MD
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.
    Hagihara M; Wiskirchen DE; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):202-7. PubMed ID: 22006007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Leonard SN
    PLoS One; 2012; 7(7):e42103. PubMed ID: 22848719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.
    Werth BJ; Vidaillac C; Murray KP; Newton KL; Sakoulas G; Nonejuie P; Pogliano J; Rybak MJ
    Antimicrob Agents Chemother; 2013 May; 57(5):2376-9. PubMed ID: 23422917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinations of cefoxitin plus other β-lactams are synergistic in vitro against community associated methicillin-resistant Staphylococcus aureus.
    Banerjee R; Fernandez MG; Enthaler N; Graml C; Greenwood-Quaintance KE; Patel R
    Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):827-33. PubMed ID: 23340864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro synergistic effects of various combinations of vancomycin and non-beta-lactams against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Kang YR; Chung DR; Kim J; Baek JY; Kim SH; Ha YE; Kang CI; Peck KR; Song JH
    Diagn Microbiol Infect Dis; 2016 Nov; 86(3):293-299. PubMed ID: 27591174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
    Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
    Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
    Kebriaei R; Rice SA; Stamper KC; Rybak MJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
    Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
    J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.
    Zheng X; Berti AD; McCrone S; Roch M; Rosato AE; Rose WE; Chen B
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.
    Singh NB; Yim J; Jahanbakhsh S; Sakoulas G; Rybak MJ
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):363-370. PubMed ID: 29807674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms.
    Kunz Coyne AJ; Stamper K; Bleick C; Kebriaei R; Lehman SM; Rybak MJ
    Microbiol Spectr; 2024 Apr; 12(4):e0321223. PubMed ID: 38411110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.